We are live on ! Find out more
ACP

Altitude Crest Partners Portfolio holdings

AUM $234M Turnover 76.47%
This Fund
S&P 500
This Quarter Est. Return
+28.94%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$234M
AUM Growth
+$84.1M
Cap. Flow
+$79.3M
Cap. Flow %
33.93%
Top 10 Hldgs %
69.27%
Holding
34
New
22
Increased
2
Reduced
4
Closed
4
Avg Time Held
0.1 years
Top 10 Avg Time Held
0.1 years
Top 20 Avg Time Held
0.1 years

Top Buys

Rank Stock Value
1
STVN icon
Stevanato
STVN
+$16.7M
2
AVBP icon
ArriVent BioPharma
AVBP
+$11.2M
3
TMO icon
Thermo Fisher Scientific
TMO
+$10.3M
4
GPCR icon
Structure Therapeutics
GPCR
+$8.65M
5
APLS icon
Apellis Pharmaceuticals
APLS
+$8.61M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$11.2M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11M
3
EXAS icon
Exact Sciences
EXAS
+$7.33M
4
BBIO icon
BridgeBio Pharma
BBIO
+$4.85M
5
ROIV icon
Roivant Sciences
ROIV
+$3.81M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
2 Miscellaneous 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
LEGN icon
1
Legend Biotech
LEGN
$3.63B
$36.6M 15.67%
652,732
+110,916
+20% +$6.69M
2023 Q4
1 quarter
DHR icon
2
Danaher
DHR
$158B
$27.1M 11.62%
108,700
-12,900
-11% -$3.15M
2023 Q4
1 quarter
BBIO icon
3
BridgeBio Pharma
BBIO
$13.3B
$18.9M 8.1%
612,060
-142,500
-19% -$4.85M
2023 Q4
1 quarter
STVN icon
4
Stevanato
STVN
$5.19B
$17.7M 7.56%
+550,000
New +$16.7M
2024 Q1
0 quarters
APLS icon
5
DELISTED
Apellis Pharmaceuticals
APLS
$16.9M 7.23%
287,277
+135,077
+89% +$8.61M
2023 Q4
1 quarter
TMO icon
6
Thermo Fisher Scientific
TMO
$251B
$10.7M 4.58%
+18,400
New +$10.3M
2024 Q1
0 quarters
AVBP icon
7
ArriVent BioPharma
AVBP
$885M
$9.9M 4.25%
+555,555
New +$11.2M
2024 Q1
0 quarters
GPCR icon
8
Structure Therapeutics
GPCR
$1.57B
$8.79M 3.76%
+205,166
New +$8.65M
2024 Q1
0 quarters
KNSA icon
9
Kiniksa Pharmaceuticals
KNSA
$6.2B
$7.9M 3.38%
400,441
-55,600
-12% -$1.09M
2023 Q4
1 quarter
JANX icon
10
Janux Therapeutics
JANX
$1.02B
$7.28M 3.12%
+193,300
New +$4.21M
2024 Q1
0 quarters
LLY icon
11
Eli Lilly
LLY
$1.11T
$7.16M 3.06%
+9,200
New +$6.55M
2024 Q1
0 quarters
BHVN icon
12
Biohaven
BHVN
$1.71B
$6.47M 2.77%
+118,380
New +$5.86M
2024 Q1
0 quarters
IMNM icon
13
Immunome
IMNM
$1.98B
$6.47M 2.77%
+262,284
New +$5.32M
2024 Q1
0 quarters
SWTX icon
14
DELISTED
SpringWorks Therapeutics
SWTX
$6.34M 2.71%
+128,842
New +$5.96M
2024 Q1
0 quarters
GERN icon
15
Geron
GERN
$771M
$5.05M 2.16%
+1,531,400
New +$3.43M
2024 Q1
0 quarters
ICLR icon
16
Icon
ICLR
$13B
$4.97M 2.13%
+14,800
New +$4.36M
2024 Q1
0 quarters
MRUS icon
17
DELISTED
Merus
MRUS
$4.95M 2.12%
+109,837
New +$4.45M
2024 Q1
0 quarters
ROIV icon
18
Roivant Sciences
ROIV
$25.1B
$4.79M 2.05%
454,766
-353,295
-44% -$3.81M
2023 Q4
1 quarter
DNLI icon
19
Denali Therapeutics
DNLI
$2.88B
$4.3M 1.84%
+209,613
New +$3.94M
2024 Q1
0 quarters
CRBP icon
20
Corbus Pharmaceuticals
CRBP
$86.3M
$4.07M 1.74%
+103,703
New +$2.56M
2024 Q1
0 quarters
AGIO icon
21
Agios Pharmaceuticals
AGIO
$2.08B
$3.31M 1.42%
+113,100
New +$3.03M
2024 Q1
0 quarters
DAWN icon
22
DELISTED
Day One Biopharmaceuticals
DAWN
$3.23M 1.38%
+195,497
New +$2.93M
2024 Q1
0 quarters
ALGS icon
23
Aligos Therapeutics
ALGS
$30.2M
$2.79M 1.19%
113,787
– –
2023 Q4
1 quarter
ENGN icon
24
enGene Therapeutics
ENGN
$106M
$2.04M 0.87%
+120,289
New +$1.47M
2024 Q1
0 quarters
APLT icon
25
DELISTED
Applied Therapeutics
APLT
$1.77M 0.76%
+259,700
New +$1.17M
2024 Q1
0 quarters
1
2

Similar funds

CM
Cohanzick Management Pleasantville, New York $231M AUM 3.17% 1-Year Est. Return
APWM
Atlas Private Wealth Management Albany, New York $238M AUM 17.48% 1-Year Est. Return
SWM
Soundmark Wealth Management Kirkland, Washington $225M AUM 17.51% 1-Year Est. Return
CC
Cipher Capital New York $216M AUM 23.63% 1-Year Est. Return
HI
Handelsinvest Investeringsforvaltning Herning, Denmark $208M AUM 35.27% 1-Year Est. Return
CC
Codex Capital New York $205M AUM 65.13% 1-Year Est. Return
DAM
Derbend Asset Management Peachtree City, Georgia $203M AUM 22.97% 1-Year Est. Return
BG
Benedetti & Gucer Atlanta, Georgia $201M AUM 25.95% 1-Year Est. Return

Altitude Crest Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Altitude Crest Partners held 34 positions worth $234M, up 56% from $149M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Altitude Crest Partners deployed $79.3M of net new capital in Q1 2024, opening 22 new positions and adding to 2 existing holdings. Its largest new stake was Stevanato: 550,000 shares worth $17.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $4.85M trimmed.

  • Altitude Crest Partners's largest Q1 2024 buy was Stevanato: 550,000 shares worth $17.7M.
  • Altitude Crest Partners added most to Apellis Pharmaceuticals in Q1 2024, an estimated $8.61M increase.
  • Altitude Crest Partners's biggest Q1 2024 reduction was BridgeBio Pharma, cutting an estimated $4.85M.
  • Altitude Crest Partners fully exited argenx in Q1 2024, selling an estimated $11.2M.
  • Altitude Crest Partners's ten largest holdings make up 69% of its $234M portfolio in Q1 2024.
  • Altitude Crest Partners opened 22 new positions and closed 4 in Q1 2024.
  • Altitude Crest Partners's portfolio value rose 56% quarter-over-quarter to $234M.

Based on Altitude Crest Partners's 13F filing for Q1 2024, filed 14 May 2024.